Publications by authors named "Ana Arencibia"

Claim this Profile
I
Isolated IgG elevation in patients with persistently normal transaminases does not affect the outcome of autoimmune hepatitis.
Álvaro Díaz-González, Ida Schregel, Lorena Carballo, Carmen Álvarez-Navascués, Enrique Frisancho-Morales

JHEP Rep· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Occurrence and Management of Opportunistic Infections in Patients With Autoimmune Hepatitis: A Spanish Multicentre Study.
María Del Barrio, Elena Ferreiro, Elena Gómez, Arantxa Caballero, Magdalena Salcedo

Aliment Pharmacol Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unveiling Drug-Induced Autoimmune-Like Hepatitis in Autoimmune Hepatitis Patients: A Multicenter Retrospective Study.
Pinelopi Arvaniti, Ignasi Olivas, Ana Pascual-Dapena, Mar Riveiro-Barciela, Paula Esteban, Ana Arencibia

Aliment Pharmacol Ther· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatic Encephalopathy and MELD-Na Predict Treatment Benefit in Autoimmune Hepatitis-related Decompensated Cirrhosis.
Pinelopi Arvaniti, Sergio Rodríguez-Tajes, Marlene Padilla, Ignasi Olivas, Ezequiel Mauro, Ana Arencibia

Clin Gastroenterol Hepatol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir.
Juan Carlos Ruiz-Cobo, Jordi Llaneras, Xavier Forns, Adolfo Gallego Moya, Isabel Conde Amiel, Ana Arencibia

Aliment Pharmacol Ther· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration.
Álvaro Díaz-González, Manuel Hernández-Guerra, Indhira Pérez-Medrano, Víctor Sapena, Mar Riveiro-Barciela

Hepatology· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study.
Anna Reig, Carmen Álvarez-Navascués, Mercedes Vergara, Elena Gómez-Domínguez, Adolfo Gallego-Moya, Ana Arencibia

Am J Gastroenterol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
Jordi Llaneras, Mar Riveiro-Barciela, Sabela Lens, Moisés Diago, Alba Cachero, Ana Arencibia

J Hepatol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4.
Zoe Mariño, Juan M Pascasio-Acevedo, Adolfo Gallego, Moisés Diago, Carme Baliellas, Ana C Arencibia

Liver Int· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spontaneous esophageal rupture (Boerhaave's syndrome). An uncommon image.
Juan Salvador Baudet, Ana Arencibia, Marta Soler, Ignacio Redondo, Guillermo Hernández

Rev Esp Enferm Dig· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis